Boehringer/Medivir: Filling Gaps, Spreading Risk
Executive Summary
Boehringer Ingelheim's generous deal with Medivir for the Swedish group's Phase II HIV compound reflects Boehringer's need to fill a gap in its HIV portfolio. It's also the latest illustration of Medivir's growing deal making wisdom. The biotech spreads risk through adding a third HIV licensing partner alongside Roche and GSK. And by holding on to Nordic marketing rights, Medivir is more likely to stay involved in development decisions.